Pharmacogenetic randomized trial for cocaine abuse: Disulfiram and α1A-adrenoceptor gene variation

European Neuropsychopharmacology

Volumn 23, Issue 11, 2013, Pages 1401-1407

  Shorter, D ^a,b   Nielsen, D A ^a,b   Huang, W ^a,b   Harding, M J ^a,b   Hamon, S C ^c   Kosten, T R ^a,b  

^a MICHAEL E DEBAKEY VETERANS AFFAIRS MEDICAL CENTER   (United States)

^b BAYLOR COLLEGE OF MEDICINE   (United States)

^c ROCKEFELLER UNIVERSITY   (United States)

Author keywords

1A adrenoceptor; Cocaine dependence; Disulfiram; Gene; Polymorphism

Indexed keywords

ALPHA 1A ADRENERGIC RECEPTOR; BENZOYLECGONINE; COCAINE; DISULFIRAM; DRUG METABOLITE; METHADONE; PLACEBO;

ADULT; ALCOHOL ABUSE; ALLELE; ARTICLE; BEHAVIOR THERAPY; CANNABIS ADDICTION; COCAINE DEPENDENCE; COGNITIVE THERAPY; CONTROLLED STUDY; DRUG DEPENDENCE; DRUG DEPENDENCE TREATMENT; DRUG DOSE INCREASE; DRUG URINE LEVEL; FEMALE; GENETIC POLYMORPHISM; GENOTYPE; HEROIN DEPENDENCE; HUMAN; MAJOR CLINICAL STUDY; MALE; METHADONE TREATMENT; OPIATE ADDICTION; PHARMACOGENETICS; PRIORITY JOURNAL; PSYCHOPHARMACOTHERAPY; RANDOMIZED CONTROLLED TRIAL; RECEPTOR GENE; TREATMENT RESPONSE;

COCAINE DEPENDENCE; DISULFIRAM; GENE; POLYMORPHISM; Α(1A)-ADRENOCEPTOR;

ADULT; ALCOHOL DETERRENTS; ALLELES; COCAINE-RELATED DISORDERS; DISULFIRAM; DOPAMINE BETA-HYDROXYLASE; FEMALE; GENOTYPE; HUMANS; MALE; METHADONE; OPIATE SUBSTITUTION TREATMENT; OPIOID-RELATED DISORDERS; POLYMORPHISM, GENETIC; RECEPTORS, ADRENERGIC, ALPHA-1;

EID: 84886791970     PISSN: 0924977X     EISSN: 18737862     Source Type: Journal    
DOI: 10.1016/j.euroneuro.2013.05.014     Document Type: Article

References (48)

1. Arnstein A.F., Mathew R., Ubriani R., Taylor J.R., Li B.M. Alpha-1 noradrenergic receptor stimulation impairs prefrontal cortical cognitive function. Biol. Psychiatry 1999, 45:26-31.
2. Baker J.R., Jatlow P., McCance-Katz E.F. Disulfiram effects on responses to intravenous cocaine administration. Drug Alcohol Depend. 2007, 87:202-209.
3. Bourdelat-Parks B.N., Anderson G.M., Donaldson Z.R., Weiss J.M., Bonsall R.W., Emery M.S., Liles L.C., Weinshenker D. Effects of dopamine beta-hydroxylase genotype and disulfiram inhibition on catecholamine homeostasis in mice. Psychopharmacology (Berl) 2005, 183:72-80.
4. Bovasso G., Cacciola J. The long-term outcomes of drug use by methadone maintenance patients. J. Behav. Health Serv. Res. 2003, 30:290-303.
5. Carboni E., Tanda G.L., Frau R., DiChiara G. Blockade of the noradrenaline carrier increases extracellular dopamine concentrations in the prefrontal cortex: evidence that dopamine is taken up in vivo by noradrenergic terminals. J. Neurochem. 1990, 55:1067-1070.
6. Carroll K.M. Manual-guided psychosocial treatment. A new virtual requirement for pharmacotherapy trials?. Arch. Gen. Psychiatry 1997, 54:923-928.
7. Carroll K.M., Nich C., Ball S.A., McCance E., Rounsaville B.J. Treatment of cocaine and alcohol dependence with psychotherapy and disulfiram. Addiction 1998, 93:713-727.
8. Carroll K.M., Fenton L.R., Ball S.A., Nich C., Frankforter T.L., Shi J., Rounsaville B.J. Efficacy of disulfiram and cognitive behavior therapy in cocaine-dependent outpatients. Arch. Gen. Psychiatry 2004, 61:264-272.
9. Cubells J.F., Kranzler H.R., McCance-Katz E., Anderson G.M., Malison R.T., Price L.H., Gerlenter J. A haplotype at the DBH locus, associated with low plasma dopamine beta-hydroxylase activity, also associates with cocaine-induced paranoia. Mol. Psychiatry 2000, 5:56-63.
10. Cubells J.F., Price L.H., Meyers B.S., Anderson G.M., Zabetian C.P., Alexopoulos G.S., Nelson J.C., Sanacora G., Kirwin P., Carpenter L., Malison R.T., Gerlenter J. Genotype-controlled analysis of plasma dopamine beta-hydroxylase activity in psychotic unipolar major depression. Biol. Psychiatry 2002, 51:358-364.
11. Cubells J.F., Zabetian C.P. Human genetics of plasma dopamine beta-hydroxylase activity: applications to research in psychiatry and neurology. Psychopharmacology (Berl) 2004, 174:463-476.
12. Gaval-Cruz M., Weinshenker D. Mechanisms of disulfiram-induced cocaine abstinence: antabuse and cocaine relapse. Mol. Interv. 2009, 9:175-187.
13. George T.P., Chawarski M.P., Pakes J., Carroll K.M., Kosten T.R., Schottenfeld R.S. Disulfiram versus placebo for cocaine dependence in buprenorphine-maintained subjects: a preliminary trial. Biol. Psychiatry 2000, 47:1080-1086.
14. Goldman D., Oroszi G., Ducci F. The genetics of addictions: uncovering the genes. Nat. Rev. Genet. 2005, 6:521-532.
15. Grella C.E., Anglin M.D., Wugalter S.E. Patterns and predictors of cocaine and crack use by clients in standard and enhanced methadone maintenance treatment. Am. J. Drug Alcohol Abuse 1997, 23:15-42.
16. Herlyn P., Muller-Hilke B., Wendt M., Hecker M., Mittlmeier T., Gradl G. Frequencies of polymorphisms in cytokines, neurotransmitters and adrenergic receptors in patients with complex regional pain syndrome type I after distal radial fracture. Clin. J. Pain 2010, 26:175-181.
17. Jiang S., Mao G., Zhang S., Hong X., Tang G., Li Z., Liu X., Zhang Y., Wang B., Xu X., Wang X. Individual and joint association of alpha1A-adrenergic receptor Arg347Cys polymorphism and plasma irbesartan concentration with blood pressure therapeutic response in Chinese hypertensive subjects. Clin. Pharmacol. Ther. 2005, 78:239-248.
18. Kosten T.R., George T.P., Kosten T.A. The potential of dopamine agonists in drug addiction. Expert Opin. Invest. Drugs 2002, 11:491-499.
19. Kosten T.R., Rounsaville B.J., Kleber H.D. Antecedents and consequences of cocaine abuse among opioid addicts. A 2.5-year follow-up. J. Nerv. Ment. Dis. 1988, 176:176-181.
20. Kosten T.R., Wu G., Huang W., Harding M.J., Hamon S.C., Lappalainen J., Nielsen D.A. Pharmacogenetic randomized trial for cocaine abuse: disulfiram and dopamine beta-hydroxylase. Biol. Psychiatry 2013, 73:219-224.
21. Lei B., Morris D.P., Smith M.P., Svetkey L.P., Newman M.F., Rotter J.I., Buchanan T.A., Beckstrom-Sternberg S.M., Green E.D., Schwinn D.A. Novel human alpha-1a-adrenocepter single nucleotide polymorphisms alter receptor pharmacology and biological function. Naunyn Schmiedebergs Arch. Pharmacol. 2005, 371:229-239.
22. Leri F., Flores J., Rodaros D., Stewart J. Blockade of stress-induced but not cocaine-induced reinstatement by infusion of noradrenergic antagonists into the bed nucleus of the stria terminalis or the nentral nucleus of the amygdala. J. Neurosci. 2002, 22:5713-5718.
23. Magura S., Rosenblum A., Rodriguez A.M. Changes in HIV risk behaviors among cocaine-using methadone patients. J. Addict. Dis. 1998, 17:71-90.
24. McCance-Katz E.F., Kosten T.R., Jatlow P. Disulfiram effects on acute cocaine administration. Drug Alcohol Depend. 1998, 52:27-39.
25. McLellan A.T., Kushner H., Metzger D., Peters R., Smith I., Grissom G., Pettinati H., Argeriou M. The fifth edition of the addiction severity index. J. Subst. Abuse Treat. 1992, 9:199-213.
26. McLellan A.T., Lewis D.C., O'Brien C.P., Kleber H.D. Drug dependence, a chronic medical illness: implications for treatment, insurance, and outcomes evaluation. JAMA 2000, 284:1689-1695.
27. Mead A.N., Rocha B.A., Donovan D.M., Katz J.L. Intravenous cocaine induced-activity and behavioural sensitization in norepinephrine but not dopamine-transporter knockout mice. Eur. J. Neurosci. 2002, 16:514-520.
28. Meandzija B., O'Connor P.G., Fitzgerald B., Rounsaville B.J., Kosten T.R. HIV infection and cocaine use in methadone maintained and untreated intravenous drug users. Drug Alcohol Depend. 1994, 36:109-113.
29. Mod L., Rihmer Z., Magyar I., Arato M., Alfoldi A., Bagdy G. Serum DBH activity in psychotic vs. nonpsychotic unipolar and bipolar depression. Psychiatry Res. 1986, 19:331-333.
30. Mutschler J., Abbruzzese E., Witt S.H., Dirican G., Nieratschker V., Frank J., Grosshans M., Rietschel M., Kiefer F. Functional polymorphism of the dopamine beta-hydroxylase gene is associated with increased risk of disulfiram-induced adverse effects in alcohol-dependent patients. J. Clin. Psychopharmacol. 2012, 32:578-580.
31. Paladini C.A., Williams J.T. Noradrenergic inhibition of midbrain dopamine neurons. J. Neurosci. 2004, 24:4568-4575.
32. Petrakis I.L., Carroll K.M., Nich C., Gordon L.T., McCance-Katz E.F., Frankforter T., Rounsaville B.J. Disulfiram treatment for cocaine dependence in methadone-maintained opioid addicts. Addiction 2000, 95:219-228.
33. Puumalu T., Riekkinen P., Sirvio J. Modulation of vigilance and behavioral activation by alpha-1 adrenoceptors in the rat. Pharmacol. Biochem. Behav. 1997, 56:705-712.
34. R_Development_Core_Team, 2009. R: A Language and Environment for Statistical Computing. Vienna, Austria, R Foundation for Statistical Computing.
35. Remme W.J. Effect of ACE inhibition on neurohormones. Eur. Heart J. 1998, 19:J16-23.
36. Rothman R., Baumann M.H. Monoamine transporters and psychostimulant drugs. Eur. J. Pharm. 2003, 479:23-40.
37. Schroeder J.P., Cooper D.A., Schank J.R., Lyle M.A., Gaval-Cruz M., Ogbonmwan Y.E., Pozdeyev N., Freeman K.G., Iuvone P.M., Edwards G.L., Holmes P.V., Weinshenker D. Disulfiram attenuates drug-primed reinstatement of cocaine seeking via inhibition of dopamine beta-hydroxylase. Neuropsychopharmacology 2010, 35:2440-2449.
38. Sheehan D.V., Lecrubier Y., Sheehan K.H., Amorim P., Janavs J., Weiller E., Hergueta T., Baker R., Dunbar G.C. The mini-international neuropsychiatric interview (M.I.N.I.): the development and validation of a structured diagnostic psychiatric interview for DSM-IV and ICD-10. J. Clin. Psychiatry 1998, 59:22-33.
39. Shorter D., Kosten T.R. Novel pharmacotherapeutic treatments for cocaine addiction. BMC Med. 2012, 2011(9):119.
40. Shorter D., Lindsay J.A., Kosten T.R. The alpha-1 adrenergic antagonist doxazosin for treatment of cocaine dependence: a pilot study. Drug Alcohol Depend. 2013, 131:66-70.
41. Snapir A., Koskenvuo J., Toikka J., Orho-Melander M., Hinkka S., Saraste M., Hartiala J., Scheinin M. Effects of common polymorphisms in the alpha1A-, alpha2B-, beta1- and beta2-adrenoceptors on haemodynamic responses to adrenaline. Clinic. Sci. (Lond) 2003, 204:509-520.
42. Stanley W.C., Li B., Bonhaus D.W., Johnson L.G., Lee K., Porter S., Walker K., Martinez G., Eglen R.M., Whiting R.L., Hedge S.S. Catecholamine modulatory effects of nepicastat (RS-25560-197), a novel, potent and selective inhibitor of dopamine-beta-hydroxylase. Br. J. Pharmacol. 1997, 121:1803-1809.
43. Sternberg D.E., van Kammen D.P., Lerner P., Ballenger J.C., Marder S.R., Post R.M., Bunney W.E. CSF dopamine beta-hydroxylase in schizophrenia. Arch. Gen. Psychiatry 1983, 40:743-747.
44. van Kammen D.P., Kelley M.E., Gilbertson M.W., Gurklis J., O'Connor D.T. CSF dopamine beta-hydroxylase in schizophrenia: associations with premorbid functioning and brain computerized tomography scan measures. Am. J. Psychiatry 1994, 151:372-378.
45. Weinshenker D. Cocaine sobers up. Nat. Med. 2010, 16:969-970.
46. Wolf B.C., Lavezzi W.A., Sullivan L.M., Middleberg R.A., Flannagan L.M. Methadone-related deaths in Palm Beach County. J. Forensic Sci. 2004, 49:375-378.
47. Zhang X.Y., Kosten T.A. Prazosin, an alpha-1 adrenergic antagonist, reduces cocaine-induced reinstatement of drug-seeking. Biol. Psychiatry 2005, 57:1202-1204.
48. Zhang X.Y., Kosten T.A. Previous exposure to cocaine enhances cocaine self-administration in an alpha-1 adrenergic receptor dependent manner. Neuropsychopharmacology 2007, 32:638-645.